Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Plos One|August 11, 2012
Human endogenous retrovirus expression is inversely associated with chronic immune activation in HIV-1 infectionChristopher E Ormsby, Devi Sengupta, Ravi Tandon, et al.
European Journal of Immunology|May 10, 2024
HIV rebound in HIV controllers is associated with a specific fecal microbiome profileYanhui Cai, Ondrej Podlaha, Steven G Deeks, et al.
The Journal of Infectious Diseases|November 8, 2024
Early Viral Dynamics Predict Human Immunodeficiency Virus Posttreatment Control After Analytic Treatment InterruptionGesham Magombedze, Elena Vendrame, Devi SenGupta, et al.
The Lancet. HIV|October 22, 2016
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trialAditya H Gaur, Hilda Kizito, Wasana Prasitsueubsai, et al.
Journal of Virology|September 2, 2011
Identification of human endogenous retrovirus-specific T cell responses in vertically HIV-1-infected subjectsRavi Tandon, Devi SenGupta, Lishomwa C Ndhlovu, et al.
Lancet (London, England)|September 5, 2017
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trialPaul E Sax, Anton Pozniak, M Luisa Montes, et al.
Communications Medicine|December 8, 2025
Predictors of virological outcomes after analytical interruption of antiretroviral therapy and HTI vaccination in early treated people with HIV-1._Lucia Bailón, Yovaninna Alarcón-Soto, José R Arribas, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 2004
Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class IIDevi SenGupta, Philip J Norris, Todd J Suscovich, et al.
Frontiers in Immunology|July 9, 2024
Circulating immune and plasma biomarkers of time to HIV rebound in HIV controllers treated with vesatolimodMohamed Abdel-Mohsen, Steven Deeks, Leila Giron, et al.
The Lancet. HIV|December 18, 2018
Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trialJoseph J Eron, Jean-Daniel Lelievre, Robert Kalayjian, et al.
Pageof 4